GlassScriptPhysician profile
Kamran Karimi
NPI 1730470220
$943.81
in general payments reported to CMS, 2019-2025
8 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.67 · 2021: $79.42 · 2022: $30.13 · 2023: $225 · 2024: $288 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $336.35 | 2019-2025 | Pristine, Impra Eptfe Vascular Grafts, Covera |
| Becton, Dickinson and Company | $319.03 | 2023-2024 | Pristine, Denali Vena Cava Filter |
| Medtronic, INC. | $146.99 | 2021-2023 | Evercross |
| Ferring Pharmaceuticals INC. | $50.42 | 2024-2025 | Euflexxa |
| Boston Scientific Corporation | $25.48 | 2024 | Opticross 35 |
| Teleflex LLC | $24.64 | 2025 | Arrow |
| Angiodynamics, INC. | $24.13 | 2023 | Soft-Vu |
| Biotronik INC. | $16.77 | 2024 | Pulsar-18 T3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.